• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab.

作者信息

Chu Yurou, Zhou Biqi, Gao Rui, Miao Miao, Qiu Huiying, Tang Xiaowen, Wang Ying, Chen Suning, Kang Liqing, Wu Depei, Xu Yang

机构信息

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, 215006, China.

Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.

出版信息

Blood Cancer J. 2025 Feb 5;15(1):11. doi: 10.1038/s41408-025-01217-9.

DOI:10.1038/s41408-025-01217-9
PMID:39910042
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11799302/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4218/11799302/8ce5798a7dd8/41408_2025_1217_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4218/11799302/8ce5798a7dd8/41408_2025_1217_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4218/11799302/8ce5798a7dd8/41408_2025_1217_Fig1_HTML.jpg

相似文献

1
Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab.CAR-T细胞疗法在先前接受blinatumomab治疗的B-ALL患者中的疗效和安全性。
Blood Cancer J. 2025 Feb 5;15(1):11. doi: 10.1038/s41408-025-01217-9.
2
Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy.blinatumomab 作为抗 CD19-CAR T 治疗后复发/难治性 B-ALL 患者失败/进展后的挽救性治疗。
Ann Med. 2023 Dec;55(1):2230888. doi: 10.1080/07853890.2023.2230888.
3
[Clinical efficacy and safety of blinatumomab bridging CAR-T cell therapy in the treatment of patients with adult acute B-cell lymphoblastic leukemia].博纳吐单抗桥接嵌合抗原受体T细胞疗法治疗成人急性B淋巴细胞白血病患者的临床疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2024 Apr 14;45(4):339-344. doi: 10.3760/cma.j.cn121090-20231127-00283.
4
Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia.嵌合抗原受体T细胞（CAR-T）免疫疗法与博纳吐单抗免疫疗法作为复发/难治性B细胞急性淋巴细胞白血病桥接移植策略的疗效与安全性比较
J Transl Med. 2025 Apr 3;23(1):391. doi: 10.1186/s12967-025-06399-1.
5
Blinatumomab Prior to CAR-T Cell Therapy-A Treatment Option Worth Consideration for High Disease Burden.嵌合抗原受体T细胞疗法前使用博纳吐单抗——高疾病负担下值得考虑的一种治疗选择
Biomedicines. 2022 Nov 13;10(11):2915. doi: 10.3390/biomedicines10112915.
6
[Targeted immunotherapy efficacy analysis in patients with relapsed/refractory B cell acute lymphocytic leukemia].复发/难治性B细胞急性淋巴细胞白血病患者的靶向免疫治疗疗效分析
Zhonghua Xue Ye Xue Za Zhi. 2022 Nov 14;43(11):946-951. doi: 10.3760/cma.j.issn.0253-2727.2022.11.011.
7
Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers.嵌合抗原受体T细胞（CAR-T）疗法和双特异性T细胞衔接器在血液系统癌症中的心脏毒性概况。
Commun Med (Lond). 2024 Jun 13;4(1):116. doi: 10.1038/s43856-024-00540-9.
8
Comparison of blinatumomab and CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia: a systematic review and meta-analysis.比较blinatumomab 和嵌合抗原受体 T 细胞疗法治疗复发/难治性急性淋巴细胞白血病：系统评价和荟萃分析。
Expert Rev Hematol. 2024 Jan-Mar;17(1-3):67-76. doi: 10.1080/17474086.2023.2298732. Epub 2024 Jan 4.
9
Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.CD19 靶向 CAR-T 细胞治疗后复发的费城染色体阳性前 B-ALL 成功地用blinatumomab 和 ponatinib 联合治疗。
Acta Haematol. 2019;141(2):107-110. doi: 10.1159/000495558. Epub 2019 Jan 29.
10
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.Blinatumomab 无应答和高疾病负担与 CD19-CAR 治疗 B-ALL 后的不良结局相关。
J Clin Oncol. 2022 Mar 20;40(9):932-944. doi: 10.1200/JCO.21.01405. Epub 2021 Nov 12.

本文引用的文献

1
Impact of prior treatment on CAR T-cell outcome in adult ALL.既往治疗对成人急性淋巴细胞白血病中嵌合抗原受体T细胞治疗结果的影响。
Blood Adv. 2024 Dec 10;8(23):6137-6138. doi: 10.1182/bloodadvances.2024014237.
2
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.Blinatumomab 治疗成人 MRD 阴性急性淋巴细胞白血病。
N Engl J Med. 2024 Jul 25;391(4):320-333. doi: 10.1056/NEJMoa2312948.
3
Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies.双特异性抗体和自体嵌合抗原受体 T 细胞疗法治疗血液系统恶性肿瘤。
Mol Ther. 2024 Aug 7;32(8):2444-2460. doi: 10.1016/j.ymthe.2024.05.039. Epub 2024 May 31.
4
Relapse/Refractory Paediatric B-ALL Case with CD19 Phenotype Switching Indicating the Importance of Appropriate Diagnostic Approach and Targeted Treatment Adjustment-Case Report.伴有 CD19 表型转换的复发/难治性小儿 B-ALL 病例提示适当诊断方法和靶向治疗调整的重要性——病例报告。
Int J Mol Sci. 2023 Aug 28;24(17):13322. doi: 10.3390/ijms241713322.
5
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.ZUMA-3 研究中，既往治疗和随后的移植对复发/难治性 B 细胞急性淋巴细胞白血病成人患者接受 brexucabtagene autoleucel 治疗结局的影响。
J Immunother Cancer. 2023 Aug;11(8). doi: 10.1136/jitc-2023-007118.
6
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse.儿童肿瘤协作组 AALL1331：在首次复发的低危 B 细胞 ALL 儿童、青少年和年轻成人中应用blinatumomab 的 III 期临床试验。
J Clin Oncol. 2023 Sep 1;41(25):4118-4129. doi: 10.1200/JCO.22.02200. Epub 2023 May 31.
7
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.四十余年来，MD 安德森对急性淋巴细胞白血病的研究与治疗的进展
J Hematol Oncol. 2023 Mar 16;16(1):22. doi: 10.1186/s13045-023-01409-5.
8
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10 and higher.Blinatumomab 与 B 细胞系急性淋巴细胞白血病患者的良好结局相关，在阈值为 10 及以上时，伴有可测量残留病阳性。
Am J Hematol. 2022 Sep;97(9):1135-1141. doi: 10.1002/ajh.26634. Epub 2022 Jun 24.
9
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.Blinatumomab 无应答和高疾病负担与 CD19-CAR 治疗 B-ALL 后的不良结局相关。
J Clin Oncol. 2022 Mar 20;40(9):932-944. doi: 10.1200/JCO.21.01405. Epub 2021 Nov 12.
10
Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.在blinatumomab 和 CAR-T 细胞治疗靶向 CD19 后，急性淋巴细胞白血病患儿中 CD19 阴性的极早正常 B 细胞前体的相对扩增：对微小残留病流式细胞术检测的影响。
Br J Haematol. 2021 May;193(3):602-612. doi: 10.1111/bjh.17382. Epub 2021 Mar 14.